睿知中国疾病研究地图
候选清单0

正在招募食管鳞状细胞癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由四川大学华西医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方四川大学华西医院West China Hospital成都医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06753747,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed as ESCC, locally advanced and unresectable, with local recurrence (local lymph node metastases) or distant metastases

    入选标准第 2 条

  3. Prior use of EGFR inhibitors or CDK4/6 inhibitors.

    排除标准第 6 条

    Residual toxicities from prior anti-tumor therapies not resolved to ≤ Grade 1 per CTCAE v5.0, except for alopecia or platinum-based therapy-induced neuropathy.

    排除标准第 9 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 5 条

  5. Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation sequencing confirmed EGFR-amplification (EGFR expression is not required in Phase 1b, but only patients with EGFR overexpression will be included in Phase 2).

    入选标准第 3 条

    Hemoglobin (Hb) ≥ 90 g/L;

    入选标准第 7 条

    Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;

    入选标准第 8 条

    Platelet count (PLT) ≥ 75 × 10⁹/L.

    入选标准第 9 条

    Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN);

    入选标准第 10 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN;

    入选标准第 11 条

    Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 60 mL/min. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%, as assessed by Doppler ultrasound.

    入选标准第 12 条

  6. Active hepatitis B (HBV DNA ≥ 2000 IU/mL or ≥ 10⁴ copies/mL), hepatitis C (anti-HCV antibody positive with detectable HCV RNA), known HIV positivity, or acquired immunodeficiency syndrome (AIDS).

    排除标准第 20 条

  7. Pregnancy or lactation.

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06753747,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age between 18 and 75 years
  2. Histologically or cytologically confirmed as ESCC, locally advanced and unresectable, with local recurrence (local lymph node metastases) or distant metastases
  3. Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation sequencing confirmed EGFR-amplification (EGFR expression is not required in Phase 1b, but only patients with EGFR overexpression will be included in Phase 2).
  4. Disease progression after first-line or subsequent lines of therapy.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  6. Adequate organ function within 7 days prior to treatment initiation, meeting the following criteria:Hematology (without transfusion, blood products, or administration of G-CSF or other hematopoietic stimulants within the past 14 days):
  7. Hemoglobin (Hb) ≥ 90 g/L;
  8. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
  9. Platelet count (PLT) ≥ 75 × 10⁹/L.
  10. Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN);
  11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN;
  12. Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 60 mL/min. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%, as assessed by Doppler ultrasound.
  13. Female patients of childbearing potential must agree to use appropriate contraception from screening until 3 months after the end of treatment and must not be breastfeeding. A negative pregnancy test is required within 7 days before the start of treatment. Male patients must agree to use appropriate contraception or have undergone surgical sterilization during the study and for 8 weeks after the last administration of study medication.
  14. All subjects are recruited on a voluntary basis and sign the informed consent. They are required to be compliant with the study and cooperative with the follow-up.

排除标准:Exclusion Criteria:

  1. Patients who have a history of other malignancies in the past five years (except for the cured basal cell carcinoma and cervical carcinoma in situ)
  2. The patient has any active autoimmune disease or a history of autoimmune disease
  3. History of severe allergic reactions or known allergies to macromolecular protein preparations, Afatinib, Palbociclib, or any component of their formulations that have resulted in hospitalization.
  4. Presence of contraindications to Palbociclib or Afatinib.
  5. Previous or planned treatments as follows:
  6. Prior use of EGFR inhibitors or CDK4/6 inhibitors.
  7. Administration of any live vaccines (e.g., influenza or varicella vaccines) within 4 weeks before the first dose or during the study.
  8. Major surgery or significant trauma within 4 weeks before the first dose.
  9. Residual toxicities from prior anti-tumor therapies not resolved to ≤ Grade 1 per CTCAE v5.0, except for alopecia or platinum-based therapy-induced neuropathy.
  10. Severe medical conditions, such as:
  11. NYHA Class II or higher heart failure.
  12. Ischemic heart disease (e.g., myocardial infarction or angina).
  13. Clinically significant supraventricular or ventricular arrhythmias.
  14. Poorly controlled diabetes (fasting blood glucose ≥ 10 mmol/L).
  15. Poorly controlled hypertension (systolic BP > 150 mmHg and/or diastolic BP > 100 mmHg).
  16. Left ventricular ejection fraction (LVEF) < 50% on echocardiography.
  17. QTc interval > 450 ms in males or > 470 ms in females.
  18. Abnormal ECG findings deemed to pose additional risk by the investigator.
  19. Active infections or unexplained fever within 48 hours prior to the first dose, or systemic antibiotic use within one week prior to informed consent.
  20. Active hepatitis B (HBV DNA ≥ 2000 IU/mL or ≥ 10⁴ copies/mL), hepatitis C (anti-HCV antibody positive with detectable HCV RNA), known HIV positivity, or acquired immunodeficiency syndrome (AIDS).
  21. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
  22. Pregnancy or lactation.
  23. Receipt of any investigational drug within 4 weeks before the first dose or concurrent enrollment in another clinical trial, except for observational (non-interventional) studies or interventional trials in follow-up.
  24. Any other factors deemed by the investigator to potentially interfere with study participation, including the ability to complete study treatment and follow-up.

引自 ClinicalTrials.gov, NCT06753747, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06753747,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06753747